Cargando…

Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?

PURPOSE: Analyse the impact of different prognostic factors on G2-late vaginal complications after vaginal brachytherapy (VBT) ± external beam radiotherapy (EBRT) in postoperative endometrial cancer (PEC). METHODS: One hundred and twenty-six PEC patients treated with VBT ± EBRT were retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaowen, Noorian, Faegheh, Abellana, Rosa, Rochera, José, Herreros, Antonio, Antelo, Gabriela, Lancellotta, Valentina, Tagliaferri, Luca, Han, Qian, Torne, Aureli, Rovirosa, Angeles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202971/
https://www.ncbi.nlm.nih.gov/pubmed/36752959
http://dx.doi.org/10.1007/s12094-023-03099-4
_version_ 1785045532665708544
author Zhang, Yaowen
Noorian, Faegheh
Abellana, Rosa
Rochera, José
Herreros, Antonio
Antelo, Gabriela
Lancellotta, Valentina
Tagliaferri, Luca
Han, Qian
Torne, Aureli
Rovirosa, Angeles
author_facet Zhang, Yaowen
Noorian, Faegheh
Abellana, Rosa
Rochera, José
Herreros, Antonio
Antelo, Gabriela
Lancellotta, Valentina
Tagliaferri, Luca
Han, Qian
Torne, Aureli
Rovirosa, Angeles
author_sort Zhang, Yaowen
collection PubMed
description PURPOSE: Analyse the impact of different prognostic factors on G2-late vaginal complications after vaginal brachytherapy (VBT) ± external beam radiotherapy (EBRT) in postoperative endometrial cancer (PEC). METHODS: One hundred and twenty-six PEC patients treated with VBT ± EBRT were retrospectively analysed considering age, body mass index, applicator diameter, clinical target volume (CTV), use of dilators, chemotherapy and EQD2((α/β=3)) at the most exposed 2 cm(3) of the CTV as prognostic factors for vaginal complications. Late vaginal complications were evaluated using objective LENT-SOMA criteria. Statistics: descriptive analysis, Chi-square, Fisher and Student tests were applied. Univariate and multivariate analyses were performed with the Baptista–Pike exact method and multiple logistic regression. RESULTS: Mean age was 65 years (SD ± 10), and median follow-up was 66 months (8–104). 19/126 patients (15%) showed G2-late vaginal complications, and 107/126 (85%) G0–G1. Univariate analysis showed: CTV ≤ 9 cm(3) (p = 0.036), use of dilators < 9 months (p = 0.015), and total ≥ 68 Gy EQD2 received by 2 cm(3) of CTV (p = 0.039) were associated with G2-late vaginal toxicity. Multivariate analysis showed the use of dilators < 9 months as an independent prognostic factor for G2-late vaginal toxicity (p = 0.043, OR 8.59, CI 1.59–159.9). CONCLUSION: The use of dilators < 9 months in VBT ± EBRT for PEC was an independent prognostic factor for G2-late vaginal toxicity. The use of vaginal dilators ≥ 9 months requires further analysis in studies evaluating late vaginal toxicity.
format Online
Article
Text
id pubmed-10202971
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-102029712023-05-24 Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)? Zhang, Yaowen Noorian, Faegheh Abellana, Rosa Rochera, José Herreros, Antonio Antelo, Gabriela Lancellotta, Valentina Tagliaferri, Luca Han, Qian Torne, Aureli Rovirosa, Angeles Clin Transl Oncol Research Article PURPOSE: Analyse the impact of different prognostic factors on G2-late vaginal complications after vaginal brachytherapy (VBT) ± external beam radiotherapy (EBRT) in postoperative endometrial cancer (PEC). METHODS: One hundred and twenty-six PEC patients treated with VBT ± EBRT were retrospectively analysed considering age, body mass index, applicator diameter, clinical target volume (CTV), use of dilators, chemotherapy and EQD2((α/β=3)) at the most exposed 2 cm(3) of the CTV as prognostic factors for vaginal complications. Late vaginal complications were evaluated using objective LENT-SOMA criteria. Statistics: descriptive analysis, Chi-square, Fisher and Student tests were applied. Univariate and multivariate analyses were performed with the Baptista–Pike exact method and multiple logistic regression. RESULTS: Mean age was 65 years (SD ± 10), and median follow-up was 66 months (8–104). 19/126 patients (15%) showed G2-late vaginal complications, and 107/126 (85%) G0–G1. Univariate analysis showed: CTV ≤ 9 cm(3) (p = 0.036), use of dilators < 9 months (p = 0.015), and total ≥ 68 Gy EQD2 received by 2 cm(3) of CTV (p = 0.039) were associated with G2-late vaginal toxicity. Multivariate analysis showed the use of dilators < 9 months as an independent prognostic factor for G2-late vaginal toxicity (p = 0.043, OR 8.59, CI 1.59–159.9). CONCLUSION: The use of dilators < 9 months in VBT ± EBRT for PEC was an independent prognostic factor for G2-late vaginal toxicity. The use of vaginal dilators ≥ 9 months requires further analysis in studies evaluating late vaginal toxicity. Springer International Publishing 2023-02-08 2023 /pmc/articles/PMC10202971/ /pubmed/36752959 http://dx.doi.org/10.1007/s12094-023-03099-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Zhang, Yaowen
Noorian, Faegheh
Abellana, Rosa
Rochera, José
Herreros, Antonio
Antelo, Gabriela
Lancellotta, Valentina
Tagliaferri, Luca
Han, Qian
Torne, Aureli
Rovirosa, Angeles
Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
title Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
title_full Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
title_fullStr Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
title_full_unstemmed Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
title_short Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
title_sort vaginal dilator use more than 9 months is a main prognostic factor for reducing g2‑late vaginal complications in 3d‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202971/
https://www.ncbi.nlm.nih.gov/pubmed/36752959
http://dx.doi.org/10.1007/s12094-023-03099-4
work_keys_str_mv AT zhangyaowen vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT noorianfaegheh vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT abellanarosa vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT rocherajose vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT herrerosantonio vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT antelogabriela vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT lancellottavalentina vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT tagliaferriluca vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT hanqian vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT torneaureli vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy
AT rovirosaangeles vaginaldilatorusemorethan9monthsisamainprognosticfactorforreducingg2latevaginalcomplicationsin3dvaginalcuffbrachytherapyinterventionalradiotherapy